Drug intelligence / Profile preview

Autologous ex vivo-expanded natural killer cells (M.D. Anderson)

Development stage: Unknown
Lead developer: University of Texas MD Anderson Cancer Center
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intraventricular

Overview

This autologous natural killer (NK) cell therapy is an investigational immunotherapy developed by M.D. Anderson Cancer Center for the treatment of recurrent or refractory malignant posterior fossa tumors in pediatric patients, specifically medulloblastoma, ependymoma, and atypical teratoid/rhabdoid tumors (AT/RT). The therapeutic process involves harvesting NK cells from the patient's own peripheral blood, followed by ex vivo expansion to significantly increase the cell count and enhance cytotoxic activity. These expanded NK cells are then administered directly into the brain ventricles via an intraventricular catheter (e.g., Ommaya reservoir). This localized delivery method is intended to bypass the blood-brain barrier and maximize the concentration of effector cells in the cerebrospinal fluid and tumor microenvironment while minimizing systemic side effects. The therapy is currently being evaluated in the Phase I NOAH (New Opportunity, Advancing Hope) clinical trial.

Other names: Autologous ex vivo-expanded NK cellsIntraventricular NK cellsNatural Killer Cell Therapy

Beyond the preview

Go deeper on Autologous ex vivo-expanded natural killer cells (M.D. Anderson).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autologous ex vivo-expanded natural killer cells (M.D. Anderson).

Explore the full profile